Literature DB >> 21107737

Analysis of thrombophilic genetic mutations in patients with Sheehan's syndrome: is thrombophilia responsible for the pathogenesis of Sheehan's syndrome?

Deniz Gokalp1, Alpaslan Tuzcu, Mithat Bahceci, Orhan Ayyildiz, Murat Yurt, Yusuf Celik, Gulistan Alpagat.   

Abstract

The gene mutations of Factor V R506Q (FV-Leiden), prothrombin (FII G20210A), methylene tetrahydrofolate reductase (MTHFR) C677T and A1298C and PAI-1 4G/5G are well-established risk factors for thrombosis. We aimed to investigate the prevalence of these gene mutations and their possible impact on the development of pathogenesis in patients with Sheehan's syndrome (SS). 40 female patients with SS compared to a control group of 45 healthy women. The presence of FV-Leiden, FII G20210A, MTHFR C677T, MTHFR A1298C and PAI-1 4G/5G gene mutations were assessed by polymerase chain reaction analysis with a light cycler analyzer. An odds ratio of greater than one is considered to increase the risk of SS disease as found in Factor V Leiden, FII G20210A, MTHFR C677T, MTHFR A1298C and PAI-1 4G/5G polymorphism, as follows respectively: 1.13, 1.85, 6.00, 8.14 and 1.45. MTHFR C677T and MTHFR A1298C polymorphism were found significantly higher in SS patients than the control group (P<0.001), however FV-Leiden, FII G20210A and PAI-1 4G/5G polymorphism showed no significant difference (P>0.05). The level of plasma total homocysteine (tHcy) was significantly higher in patients with SS than in the control group (P<0.001). We suggest that the genetic mutations of FV-Leiden, FII G20210A, MTHFR C677T, MTHFR A1298C and PAI-1 4G/5G increase the risk of SS. Also, high plasma tHcy levels may be a risk factor for the development of SS. © Springer Science+Business Media, LLC 2010

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21107737     DOI: 10.1007/s11102-010-0276-x

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  31 in total

1.  Atypical presentation of Sheehan's syndrome without postpartum haemorrhage.

Authors:  D Gupta; M Gaiha; R Mahajan; M K Daga
Journal:  J Assoc Physicians India       Date:  2001-03

2.  PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects.

Authors:  R Seguí; A Estellés; Y Mira; F España; P Villa; C Falcó; A Vayá; S Grancha; F Ferrando; J Aznar
Journal:  Br J Haematol       Date:  2000-10       Impact factor: 6.998

3.  The prevalence of factor V Leiden (1691 G-->A) mutation in Turkey.

Authors:  A Gürgey; L Mesci
Journal:  Turk J Pediatr       Date:  1997 Jul-Sep       Impact factor: 0.552

4.  A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?

Authors:  N M van der Put; F Gabreëls; E M Stevens; J A Smeitink; F J Trijbels; T K Eskes; L P van den Heuvel; H J Blom
Journal:  Am J Hum Genet       Date:  1998-05       Impact factor: 11.025

5.  Recurrent miscarriage syndrome and infertility due to blood coagulation protein/platelet defects: a review and update.

Authors:  Rodger L Bick; Debra Hoppensteadt
Journal:  Clin Appl Thromb Hemost       Date:  2005-01       Impact factor: 2.389

6.  A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity.

Authors:  I Weisberg; P Tran; B Christensen; S Sibani; R Rozen
Journal:  Mol Genet Metab       Date:  1998-07       Impact factor: 4.797

7.  Prothrombin G20210A gene mutation with LightCycler polymerase chain reaction in venous thrombosis and healthy population in the southeast of Turkey.

Authors:  Orhan Ayyildiz; Sevgi Kalkanli; Sabri Batun; Mehmet Aybak; Abdurrahman Isikdogan; Naci Tiftik; Zahit Bolaman; Murat Soker; Ekrem Muftuoglu
Journal:  Heart Vessels       Date:  2004-07       Impact factor: 2.037

8.  Plasminogen activator inhibitor 1 4G/5G polymorphism and coagulation factor XIII Val34Leu polymorphism: impaired fibrinolysis and early pregnancy loss.

Authors:  Astrid Dossenbach-Glaninger; Michael van Trotsenburg; Martin Dossenbach; Christian Oberkanins; Anne Moritz; Walter Krugluger; Johannes Huber; Pierre Hopmeier
Journal:  Clin Chem       Date:  2003-07       Impact factor: 8.327

9.  Hyperhomocysteinemia as a risk factor for deep-vein thrombosis.

Authors:  M den Heijer; T Koster; H J Blom; G M Bos; E Briet; P H Reitsma; J P Vandenbroucke; F R Rosendaal
Journal:  N Engl J Med       Date:  1996-03-21       Impact factor: 91.245

10.  Pituitary autoimmunity in patients with Sheehan's syndrome.

Authors:  Ravinder Goswami; Narayana Kochupillai; Patricia A Crock; Abdul Jaleel; Nandita Gupta
Journal:  J Clin Endocrinol Metab       Date:  2002-09       Impact factor: 5.958

View more
  6 in total

Review 1.  Sheehan's syndrome: new insights into an old disease.

Authors:  Halit Diri; Zuleyha Karaca; Fatih Tanriverdi; Kursad Unluhizarci; Fahrettin Kelestimur
Journal:  Endocrine       Date:  2015-09-01       Impact factor: 3.633

2.  GENETIC DISORDERS OF PITUITARY DEVELOPMENT IN PATIENTS WITH SHEEHAN'S SYNDROME.

Authors:  H Diri; E F Sener; F Bayram; M Dundar; Y Simsek; O Baspinar; G Zararsiz
Journal:  Acta Endocrinol (Buchar)       Date:  2016 Oct-Dec       Impact factor: 0.877

3.  Sheehan's syndrome: Newer advances.

Authors:  C Shivaprasad
Journal:  Indian J Endocrinol Metab       Date:  2011-09

4.  Combined choroidal neovascularization and hypopituitarism in a patient with homozygous mutation in methylenetetrahydrofolate reductase gene.

Authors:  Aydogan Aydogdu; Cem Haymana; Kamil Baskoy; Ali H Durukan; Gokhan Ozgur; Omer Azal
Journal:  J Res Med Sci       Date:  2014-01       Impact factor: 1.852

5.  The Symptoms Get Worse after Pregnancy in Sheehan's Syndrome: A Case Report.

Authors:  Jingwen Hao; Min Liu; Zhaohui Mo
Journal:  Case Rep Med       Date:  2012-09-19

6.  Etiopathogenesis of Sheehan's Syndrome: Roles of Coagulation Factors and TNF-Alpha.

Authors:  Halit Diri; Elif Funda Sener; Fahri Bayram; Nazife Tascioglu; Yasin Simsek; Munis Dundar
Journal:  Int J Endocrinol       Date:  2014-04-10       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.